Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:INNTNASDAQ:PULMNASDAQ:SBPHNASDAQ:SEELNASDAQ:UMRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shsN/APULMPulmatrix$2.09+3.5%$1.86$1.55▼$3.14$7.63M0.9217,656 shs4,090 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/ASEELSeelos Therapeutics$0.30-9.1%$0.74$0.29▼$49.80$4.12M1.88430,273 shs610,410 shsUMRXCogent Biosciences$6.54-6.0%$10.50$0.29▼$3.72$277.75M3.931.22 million shs1.51 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.91%PULMPulmatrix+0.50%-4.71%+20.96%+6.33%-30.82%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SEELSeelos Therapeutics+0.43%-15.06%-35.45%-69.71%-98.44%UMRXCogent Biosciences-2.25%+7.74%+8.92%+50.32%-38.08%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix0.9912 of 5 stars3.53.00.00.00.00.00.6SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos Therapeutics1.8876 of 5 stars3.24.00.00.00.60.00.0UMRXCogent BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINNTInnovate BiopharmaceuticalsN/AN/AN/AN/APULMPulmatrix3.00Buy$10.00378.47% UpsideSBPHSpring Bank PharmaceuticalsN/AN/AN/AN/ASEELSeelos Therapeutics2.33Hold$70.0023,155.81% UpsideUMRXCogent BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/APULMPulmatrix$7.30M1.05N/AN/A$4.93 per share0.42SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/ASEELSeelos Therapeutics$2.20M1.87N/AN/A($3.42) per share-0.09UMRXCogent Biosciences$22.50M12.34N/AN/A$1.04 per share6.29Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/APULMPulmatrix-$14.12M-$3.86N/A∞N/A-193.49%-63.94%-40.88%5/10/2024 (Estimated)SBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/ASEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)UMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/ALatest INNT, UMRX, SBPH, PULM, and SEEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PULMPulmatrixN/A-$0.57-$0.57-$0.57N/A$2.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINNTInnovate BiopharmaceuticalsN/A0.350.35PULMPulmatrixN/A5.335.33SBPHSpring Bank PharmaceuticalsN/A5.115.11SEELSeelos TherapeuticsN/A0.140.14UMRXCogent Biosciences0.182.902.90OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINNTInnovate Biopharmaceuticals5.88%PULMPulmatrix11.84%SBPHSpring Bank Pharmaceuticals17.17%SEELSeelos Therapeutics23.37%UMRXCogent Biosciences26.39%Insider OwnershipCompanyInsider OwnershipINNTInnovate Biopharmaceuticals7.90%PULMPulmatrix3.61%SBPHSpring Bank Pharmaceuticals12.70%SEELSeelos Therapeutics5.40%UMRXCogent Biosciences31.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionablePULMPulmatrix223.65 million3.52 millionNot OptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableINNT, UMRX, SBPH, PULM, and SEEL HeadlinesSourceHeadlineCogent Biosciences Incmoney.usnews.com - April 24 at 4:34 AMAnalysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)markets.businessinsider.com - February 26 at 5:33 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)markets.businessinsider.com - February 26 at 8:53 AMCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Resultsmarkets.businessinsider.com - February 26 at 8:53 AMBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potentialmarkets.businessinsider.com - February 15 at 8:43 AMCogent Biosciences Stock Soars After $225M Private Placementmarketwatch.com - February 14 at 10:02 AMCogent Biosciences announces oversubscribed $225M private placementmsn.com - February 14 at 10:02 AMBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospectsmarkets.businessinsider.com - February 9 at 2:23 AMCiti starts Cogent Biosciences at buy, cites GI tumor drug potentialmsn.com - February 8 at 4:22 PMBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trialmarkets.businessinsider.com - December 15 at 7:55 PMMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinibmarkets.businessinsider.com - December 13 at 5:33 PMDow Surges 100 Points; Cogent Biosciences Shares Plungemarkets.businessinsider.com - December 11 at 12:21 PMCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatmentmarkets.businessinsider.com - December 11 at 12:21 PMCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosismarkets.businessinsider.com - December 11 at 10:08 AMCogent slumps after mid-stage data for rare disorder therapymsn.com - December 11 at 10:08 AMPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Sharesmarkets.businessinsider.com - November 21 at 9:11 AMPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciencesmarkets.businessinsider.com - November 14 at 8:40 AMPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciencesmarkets.businessinsider.com - November 4 at 5:21 PMPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Ratingmarkets.businessinsider.com - October 28 at 7:55 AMAnalyst Expectations for Cogent Biosciences's Futurebenzinga.com - August 30 at 8:53 AMCogent Biosciences Is Beginning To Differentiate Its KIT Inhibitormsn.com - August 15 at 5:40 PMLifeSci Capital Remains a Buy on Cogent Biosciences (COGT)markets.businessinsider.com - August 8 at 3:59 PMDoes Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?msn.com - July 11 at 1:47 PMCogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisitionmarketwatch.com - June 13 at 11:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInnovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Spring Bank PharmaceuticalsNASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Cogent BiosciencesNASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.